GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy
STAMFORD, Conn., Dec. 01, 2023 (GLOBE NEWSWIRE) — GeneDx (Nasdaq:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced new data to be presented at the American Epilepsy Society (AES) annual meeting in Orlando, Florida, December 1-5, 2023, that supports the use of exome sequencing as a first-tier test for patients with epilepsy.